{
    "clinical_study": {
        "@rank": "16687", 
        "arm_group": [
            {
                "arm_group_label": "PEX168 100 microgram", 
                "arm_group_type": "Experimental", 
                "description": "PEX168 100 microgram qw sc. and the medication continued for 12 weeks"
            }, 
            {
                "arm_group_label": "PEX168 200 microgram", 
                "arm_group_type": "Experimental", 
                "description": "PEX168 200 microgram qw sc. and the medication continued for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo qw sc. and the medication continued for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1)\n      analogue that created on the basis of the Exenatide and modified by polyethylene glycol\n      (PEG).\n\n      This study aims to evaluate the effective therapeutic concentration range of PEX168, also\n      decided to observe safety and PK/PD correlation by long-term continuous administration."
        }, 
        "brief_title": "A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Has been diagnosed with type 2 diabetes mellitus.\n\n          2. Has been treated with a stable dose of metformin monotherapy \u2265 12 weeks before\n             randomization, and metformin dose \u2265 1500 mg / day.\n\n          3. Has HbA1c of 7.5% to 11.0%(local) at screening. And has HbA1c of 7.0% to\n             11.0%(Central) before randomization.\n\n          4. Is 20 to 70 years old, inclusive.\n\n          5. Has a body mass index (BMI) of 19 kg/m2 to 35 kg/m2, inclusive.\n\n        Exclusion Criteria:\n\n          1. Skin test of PEX168 is positive.\n\n          2. Is currently treated with any of the following excluded medications:\n\n               -  GLP-1 or GLP-1 analogues prior to study start;\n\n               -  Insulin within 6 months prior to study start;\n\n               -  Growth hormone within 6 months prior to study start;\n\n               -  Abuse of drug or alcohol within 6 months prior to study start;\n\n               -  Any other hypoglycemic drugs (including Chinese herbal medicine) except for\n                  metformin within 3 months prior to study start;\n\n               -  Any clinical trials of drugs or medical instruments within 3 months prior to\n                  study start;\n\n               -  Systemic corticosteroids by oral, parenteral, or intra-articular route\n\n               -  Any drugs for weight loss or operations leading to weight instable within 2\n                  months prior to study start;\n\n               -  Any drugs that may interfere the evaluation of safety and efficiency of\n                  investigated drugs, drugs or herbals medicine that may result in toxicity to\n                  main organs prior to study start;\n\n          3. A history or evidence of any of the following :\n\n               -  Severe hypoglycemia history (e.g., sleepiness, consciousness disorder,\n                  deliration, coma led by hypoglycemia);\n\n               -  Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury,\n                  or secondary forms of diabetes (e.g., Cushing's syndrome or\n                  acromegaly-associated diabetes);\n\n               -  Acute or chronic gastrointestinal diseases that were not suitable for the trials\n                  evaluated by investigators;\n\n               -  Hypertension with SBP>140mmHg, and/or DBP >90mmHg after antihypertensive\n                  therapy;\n\n               -  Severe cardiovascular diseases histories including congestive heart failure\n                  (NYHA III or IV), unstable angina, stroke or TIA, myocardial\n                  infarction,sustained and clinically relevant ventricular arrhythmia, coronary\n                  artery bypass surgery or percutaneous coronary intervention;\n\n               -  Acute or chronic pancreatitis history, or pancreas injury history, or any high\n                  risk factors which may result in pancreatitis;\n\n               -  Malignancy of any organ system (other than localized basal cell carcinoma of the\n                  skin), treated or untreated, regardless of whether there is evidence of local\n                  recurrence or metastases;\n\n               -  Medullary thyroid carcinoma history, or multiple endocrine neoplasia history;\n\n               -  Acute metabolic complications such as ketoacidosis, lactic acidosis, or\n                  hyperosmolar state (coma) , or maculopathy , or instability of proliferative\n                  retinopathy within the past 6 months;\n\n               -  Weight change is over 10% within 3 months prior to the study start;\n\n          4. Any of the following significant laboratory abnormalities:\n\n               -  Alanine aminotrasferase (ALT) and/or asparatate aminotransferase (AST)>2*upper\n                  limit of normal (ULN), and/or total bilirubin>1.5*ULN, confirmed by repeat\n                  measure;\n\n               -  Creatinine > upper limit of normal, confirmed by repeat measure, and/or\n                  proteinurea>++ and 24 hour urinary protein quantitative \u22651g;\n\n               -  Fasting plasma triglyceride \u2265 5.64 mmol/L (500mg/dL);\n\n               -  Thyroid dysfunction unsuitable for this trial evaluated by investigator;\n\n               -  Hemodlastase > upper limit of normal, confirmed by repeat measure;\n\n          5. Male or female fertility are reluctant to take contraceptive method during the test,\n             pregnancy or lactating women;\n\n          6. Any other situations which may result in the withdrawal of subjects or bring\n             significant risk to subjects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965509", 
            "org_study_id": "PEX168-I-06"
        }, 
        "intervention": {
            "arm_group_label": [
                "PEX168 100 microgram", 
                "PEX168 200 microgram", 
                "Placebo"
            ], 
            "description": "injection has to administered subcutaneously weekly", 
            "intervention_name": "PEX168 or placebo", 
            "intervention_type": "Drug", 
            "other_name": "Polyethylene Glycol Loxenatide or Placebo"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PEX168", 
            "Phase I/II", 
            "add on to metformin"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "China-Japan Friendship Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin", 
        "other_outcome": [
            {
                "measure": "To assess the body weights after the treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "To assess number of participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "China-Japan Friendship Hospital", 
            "last_name": "Wenying Yang, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To assess HbA1C levels after treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965509"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To assess Fasting blood glucose levels", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "China-Japan Friendship Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}